LIN28A Modulates Splicing and Gene Expression Programs in Breast Cancer Cells

Area of Science:

• Molecular Biology
• Cancer Research
• Genomics

Background:

• LIN28 is an RNA-binding protein crucial for development and cancer, but its oncogenic mechanisms are unclear.
• Understanding LIN28's role in breast cancer is vital for developing targeted therapies.

Purpose of the Study:

• To elucidate the molecular mechanisms of LIN28's oncogenic properties in breast cancer.
• To identify LIN28-interacting proteins and their downstream effects on gene expression and splicing.

Main Methods:

• RNA-protein immunoprecipitation coupled with genome-wide sequencing (RIP-Seq) to identify LIN28-bound mRNAs.
• Small interfering RNA (siRNA) knockdown of LIN28 and hnRNP A1 followed by computational analysis of differential splicing.
• Analysis of publicly available breast cancer array data (TCGA).

Main Results:

• LIN28 binds to 843 mRNAs in breast cancer cells, many involved in RNA and cell metabolism.
• hnRNP A1 identified as a LIN28-interacting partner, both regulating alternative splicing and mRNA expression.
• LIN28 depletion causes ENAH gene isoform switching, decreasing ENAH exon 11a isoform expression, which is elevated in HER2-positive breast cancers.
• LIN28 expression differs significantly in the HER2 subtype compared to other breast cancer subtypes in TCGA data.

Conclusions:

• LIN28 regulates alternative splicing and gene expression programs in breast cancer.
• LIN28's interaction with hnRNP A1 and its role in ENAH splicing suggest a mechanism for its oncogenic activity.
• LIN28 may contribute to specific breast cancer subtype phenotypes, particularly HER2-positive breast cancer.